Summary
Genetic Analysis AS (Genetic Analysis) is a molecular diagnostic company that mapping of microbiota by utilizing the GA-map technology to develop IVD tests in various diseases. The company develops gene-based routine tests for the mapping and diagnosis of diseases related to dysbiosis and bacterial imbalances in the digestive system of irritable bowel syndrome and IBD patients. It services include gut microbiota, patient testing and clinical research services. Genetic Analysis' technology utilizes common and variable DNA sequences within specified 16S rRNA gene of the bacteria to identify the different bacteria. Its GA-map ProbeTool software program uses search mechanisms to find combinations of DNA probes that can be used in the test. The company's GA-map technology helps to generate profiles of a person’s microbiota and correlate such profiles to different health conditions. Genetic Analysis is headquartered in Oslo, Norway.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Genetic Analysis AS
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
- Genetic Analysis AS Company Overview
- Genetic Analysis AS Company Snapshot
- Genetic Analysis AS Pipeline Products and Ongoing Clinical Trials Overview
- Genetic Analysis AS – Pipeline Analysis Overview
- Genetic Analysis AS - Key Facts
- Genetic Analysis AS - Major Products and Services
- Genetic Analysis AS Pipeline Products by Development Stage
- Genetic Analysis AS Pipeline Products Overview
- GA-map Diabetes II
- GA-map Diabetes II Product Overview
- GA-map Dysbiosis Test
- GA-map Dysbiosis Test Product Overview
- GA-map Obesity
- GA-map Obesity Product Overview
- Genetic Analysis AS - Key Competitors
- Genetic Analysis AS - Key Employees
- Genetic Analysis AS - Locations And Subsidiaries
- Head Office
- Recent Developments
- Genetic Analysis AS, Recent Developments
- Aug 22, 2016: Beijing HuayiHuilang Medical Instrument Co to Distribute GA-map Dysbiosis Test in China
- May 18, 2015: Genetic Analysis: A Novel Diagnostic Test for Determining Dysbiosis in IBS and IBD Patients
- Mar 27, 2015: New CEO and Chairman of Genetic Analysis
- Jan 08, 2015: Genetic Analysis signs exclusive German distribution agreement with Labor Dr. Bayer/synlab for GA-map Dysbiosis test
- Nov 18, 2014: Genetic Analysis pens first pharma collaboration with US Rebiotix
- Oct 15, 2013: Genetic Analysis Launches New DNA-Based GA-map IBS Dysbiosis Test at UEGW 2013
- Oct 01, 2013: Genetic Analysis secures $2 million to fund launch of new DNA-based GA-map IBS Dysbiosis Test
- Sep 19, 2013: Genetic Analysis participates in an EU project
- Feb 17, 2013: Genetic Analysis appoints Kari Stenersen as new CEO
- Nov 09, 2012: Genetic Analysis AS to present a Poster at Advances in IBD meeting, Florida 13 - 15 December 2012
- Appendix
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Genetic Analysis AS Pipeline Products and Ongoing Clinical Trials Overview
- Genetic Analysis AS Pipeline Products by Equipment Type
- Genetic Analysis AS Pipeline Products by Indication
- Genetic Analysis AS, Key Facts
- Genetic Analysis AS, Major Products and Services
- Genetic Analysis AS Number of Pipeline Products by Development Stage
- Genetic Analysis AS Pipeline Products Summary by Development Stage
- GA-map Diabetes II - Product Status
- GA-map Diabetes II - Product Description
- GA-map Dysbiosis Test - Product Status
- GA-map Dysbiosis Test - Product Description
- GA-map Obesity - Product Status
- GA-map Obesity - Product Description
- Genetic Analysis AS, Key Employees
- Glossary
- List of Figures
- Genetic Analysis AS Pipeline Products by Equipment Type
- Genetic Analysis AS Pipeline Products by Development Stage